Medtronic gets Medicare coverage for leadless pacemaker

Micra Transcatheter Pacing System (right) compared with a traditional pacemaker. (Medtronic)

Medtronic has secured Medicare coverage for its leadless pacemaker, Micra Transcatheter Pacing System (TPS). The Centers for Medicare & Medicaid Services (CMS) agreed to cover Micra TPS through its Coverage with Evidence Development, a policy that adds products to Medicare provided the manufacturer generates additional data.

The terms of the agreement mean Medicare, a U.S. federal health insurance program for people aged 65 or older, will only start covering Micra TPS once the CMS has approved two studies. Medtronic is seeking coverage of an existing postapproval trial and a planned study tracking longitudinal data on patients in the Medicare population. The postapproval trial is looking at the acute complication rate and long-term complication-free survival in patients who receive Micra TPS in the real world.

By adding a study focused on the Medicare population to its postapproval activities, Medtronic has secured Medicare coverage of patients in the trials nine months after FDA cleared the device for use in people who need a single-chamber pacemaker.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

"Medtronic is pleased with the CMS decision to cover leadless pacemakers, which will allow broad patient access to this novel, minimally invasive pacemaker technology through an innovative approach to evidence and data collection to address research questions identified by CMS," Medtronic SVP John Liddicoat said in a statement.

Micra TPS stands apart from traditional pacemakers because of its size. At one inch long, the device is considerably smaller—Medtronic claims 93% smaller—than traditional pacemakers. And, unlike the competition, it is leadless. The device is hooked on to the heart using small prongs.

Medtronic thinks the design cuts the risk of complication. The complication rate in a 719-person trial came in below 7%. Subsequent long-term follow-up data linked Micra TPS to a 47% drop in risk of hospitalization and an 82% fall in the risk of the device needing removal, repositioning or replacement.

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.